Adventrx hopes to find a new pathway for ANX-530
This article was originally published in Pharmaceutical Approvals Monthly
Adventrx will meet with FDA April 20 to discuss the agency's refuse-to-file letter for its chemotherapy drug, ANX-530. The sponsor submitted its NDA in December 2009, but announced March 1 that FDA rejected the application because the data included in the submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. This chemistry, manufacturing and controls issue was the only reason for the RTF letter, FDA said. Adventrx is hoping to position ANX-530 as a safer therapeutic option to the currently marketed Navelbine and Taxotere
You may also be interested in...
The US FDA released two device-related close-out letters in September. One of the letters carries a January 2020 date, but previously was not publicly available.
The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.
The US agency has announced another month of webinars aimed at labs and manufacturers that are developing – or have developed – diagnostic tests for the novel coronavirus.